MAOA and MAOB are mitochondrialouter-membrane enzymes that break the Cα–N bond of arylalkylamines,including neurotransmitters like dopamine, through a FAD-dependentoxidative deamination, and both enzymes play a role in age-relatedneurological disorders.26 In particular,MAOB is a validated drug target for Parkinson’s disease27 and multiple lines of evidence suggest thatMAOB is involved also in Alzheimer’s disease.28 Therefore, targeting both NOXs and MAOs may be a promisingpharmacological strategy to mitigate ROS-mediated neuroinflammationand neuronal damage. The gene discussed is MAOB; the disease is early-onset autosomal dominant Alzheimer disease.